ScholarIQanswers from OpenAlex

A Population-Based Analysis of the Risk of Glomerular Disease Relapse after COVID-19 Vaccination

PaperCitations, authors & open-access status

A Population-Based Analysis of the Risk of Glomerular Disease Relapse after COVID-19 Vaccination is a paper indexed in ScholarIQ from OpenAlex.

How many citations does A Population-Based Analysis of the Risk of Glomerular Disease Relapse after COVID-19 Vaccination have?

ScholarIQcitation count

A Population-Based Analysis of the Risk of Glomerular Disease Relapse after COVID-19 Vaccination has 49 citations in the OpenAlex counts ScholarIQ stores.

When was A Population-Based Analysis of the Risk of Glomerular Disease Relapse after COVID-19 Vaccination published?

ScholarIQyear

A Population-Based Analysis of the Risk of Glomerular Disease Relapse after COVID-19 Vaccination has 2022 year in the ScholarIQ index.

What is the open-access status of A Population-Based Analysis of the Risk of Glomerular Disease Relapse after COVID-19 Vaccination?

ScholarIQoa status

A Population-Based Analysis of the Risk of Glomerular Disease Relapse after COVID-19 Vaccination has green oa status in the ScholarIQ index.

What is the DOI of A Population-Based Analysis of the Risk of Glomerular Disease Relapse after COVID-19 Vaccination?

ScholarIQdoi

The DOI for A Population-Based Analysis of the Risk of Glomerular Disease Relapse after COVID-19 Vaccination is on the source record.

What is the PMID of A Population-Based Analysis of the Risk of Glomerular Disease Relapse after COVID-19 Vaccination?

ScholarIQpmid

The PMID for A Population-Based Analysis of the Risk of Glomerular Disease Relapse after COVID-19 Vaccination is on the source record.

What is the OpenAlex record for A Population-Based Analysis of the Risk of Glomerular Disease Relapse after COVID-19 Vaccination?

ScholarIQopenalex

The OpenAlex for A Population-Based Analysis of the Risk of Glomerular Disease Relapse after COVID-19 Vaccination is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial